Ataseven Eda, Yilmaz Şebnem, Tüfekçi Özlem, Ören Hale
Division of Pediatric Hematology and Oncology, Department of Pediatric Hematology-Oncology, Ege University Faculty of Medicine.
Department of Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
J Pediatr Hematol Oncol. 2023 Jan 1;45(1):25-28. doi: 10.1097/MPH.0000000000002600. Epub 2022 Nov 24.
Central venous lines (CVL) in children with acute lymphoblastic leukemia (ALL) provide comfortable administration of intensive chemotherapy and blood sampling. The optimal time for the insertion of CVL in patients with ALL during induction therapy is controversial. This study aimed to investigate the frequency of CVL-related complications in children with ALL concerning the time of CVL insertion.
We reviewed the records of 52 pediatric ALL patients with CVL. CVL placement before or on treatment day 15 was defined as "early insertion", and after treatment day 15 was defined as "late insertion". Demographics, preoperative blood counts, type of central line, time of CVL placement, CVL-related complications, and blood counts during complications were all noted. All the data were collected from those with the first catheter use.
CVL was placed ≤15 days in 26 patients (50%) and after 15 days in 26 patients (50%). Regarding the infection rates, no statistical difference was found between early and late CVL-inserted groups ( P =n.s.). Five patients developed thrombosis, and risk was found to be similar between early and late CVL-inserted groups ( P =n.s.). Catheter-related mechanical complications were recorded in 7 patients (3 in early and 4 in late CVL-inserted group, ( P =n.s.).
The present study showed no relation between the timing of CVL placement during induction therapy and the occurrence of infection and thrombosis. Our results suggest that CVL can be placed safely at the time of diagnosis or early induction treatment to provide a comfortable administration of chemotherapy and decrease painful blood samplings.
急性淋巴细胞白血病(ALL)患儿的中心静脉置管(CVL)便于进行强化化疗给药及采血。ALL患者诱导治疗期间CVL的最佳置入时间存在争议。本研究旨在调查ALL患儿CVL相关并发症的发生频率与CVL置入时间的关系。
我们回顾了52例置有CVL的儿科ALL患者的记录。将治疗第15天或之前置入CVL定义为“早期置入”,治疗第15天后置入定义为“晚期置入”。记录人口统计学资料、术前血细胞计数、中心静脉导管类型、CVL置入时间、CVL相关并发症以及并发症期间的血细胞计数。所有数据均收集自首次使用导管的患者。
26例患者(50%)在≤15天置入CVL,26例患者(50%)在15天后置入CVL。就感染率而言,早期和晚期CVL置入组之间未发现统计学差异(P =无显著性差异)。5例患者发生血栓形成,早期和晚期CVL置入组的风险相似(P =无显著性差异)。7例患者记录了导管相关机械并发症(早期CVL置入组3例,晚期CVL置入组4例,P =无显著性差异)。
本研究表明诱导治疗期间CVL置入时间与感染和血栓形成的发生无关。我们的结果表明,在诊断时或早期诱导治疗时可安全置入CVL,以便于舒适地进行化疗给药并减少痛苦的采血。